Evidence overview
Probiotics
Probiotics are live microorganisms studied across an unusually broad range of indications, with established uses in pediatric and antibiotic-associated diarrhea, irritable bowel syndrome, and several other areas. The single most-important factor for consumers is strain specificity: "probiotics work for X" only makes sense as a claim about a specific strain at a specific dose, since different strains have substantially different effects.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Live microorganisms intended to confer health benefits when consumed in adequate amounts. Effects are...
Study coverage
Study coverage by goal
PubMed counts for Probiotics grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Probiotics.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Probiotics are live microorganisms studied across an unusually broad range of indications: antibiotic-associated diarrhea (the most-clinically-established use), irritable bowel syndrome (IBS), pediatric acute infectious diarrhea, Clostridioides difficile infection prevention, inflammatory bowel disease, allergic conditions, immune support, mood and the gut-brain axis (a rapidly growing research area), and women's health applications including bacterial vaginosis. The most-studied genera are Lactobacillus, Bifidobacterium, and Saccharomyces boulardii (a yeast); individual species and strains within these genera have substantially different effects, which is the most-important practical detail in the entire literature.
The outcome dimensions covered most heavily are antibiotic-associated diarrhea in adults and children (the most-clinically-established use, with practice-guideline endorsement from major pediatric and adult gastroenterology bodies), irritable bowel syndrome (multiple network meta-analyses), inflammatory bowel disease (mixed evidence depending on indication and strain), prevention of nosocomial infections in specific populations, atopic dermatitis prevention in infants of allergic parents, and (more recently) mood and anxiety in the broader gut-brain-axis literature. The World Gastroenterology Organisation maintains a global practice guideline that organizes the field around strain-and-indication-specific recommendations.
Demographically, the literature is unusually broad across populations: pediatric diarrhea trials dominate the public-health side of probiotic research; older adults are heavily studied for AAD prevention; women of reproductive age feature in vaginal-health research. Strain specificity is the central methodological and consumer-relevant issue: meta-analyses sometimes pool trials by intervention category (for example, 'probiotics for IBS') rather than by specific strain, which dilutes the signal. Consumer products often disclose only the genus and species but not the specific strain identifier, which makes evidence-matching difficult in practice.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Probiotics are generally well-tolerated in healthy individuals at recommended doses. The most-common adverse effects are transient bloating, gas, and abdominal discomfort, typically resolving within the first week of use. No tolerable upper limit has been established. The major safety concerns are not in healthy users but in specific clinical populations: immunocompromised individuals (chemotherapy, transplant recipients, advanced HIV), critically ill patients (especially with central venous catheters, where rare cases of bacteremia or fungemia have been reported), preterm infants, and individuals with severely compromised gut barrier function. Drug interactions are minimal, but probiotic administration should typically be separated from antibiotic dosing by at least 2 hours to maintain viability. People in any of the high-risk clinical populations should consult a clinician before use.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
The most comprehensive supplement-level practice guideline available for probiotics, organizing the field's strain-and-indication-specific recommendations into a single reference document. The clearest practice-guideline anchor for probiotic supplementation.
View on PubMedExpert-society position from ESPGHAN on probiotics for antibiotic-associated diarrhea in children - the most-clinically-established use of probiotics and a population where strain-specific recommendations are well-developed.
View on PubMedRecent network meta-analysis on probiotics within the broader IBS-intervention literature (scope also includes prebiotics, synbiotics, and fecal microbiota transplantation). Establishes the modern reference for probiotic positioning in IBS, where probiotics are one of several intervention categories the field is comparing.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the probiotics literature at a general level. The single most-consequential issue it does not address is strain selection: different strains within the same genus have substantially different effects, and consumer-product labeling often does not disclose the specific strain identifier. It also does not address which dose to use, how long to take a probiotic for your goal, whether your current health context flags any of the high-risk safety populations, or how the broader prebiotics-and-synbiotics-and-fermented-foods category might be more or less suited to your case. Strain specificity makes the personalized report unusually useful for probiotics.
Personalized to you
Get a personalized Probiotics report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Probiotics materially updates. No account required.